CN102961704A - Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof - Google Patents
Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof Download PDFInfo
- Publication number
- CN102961704A CN102961704A CN2012104715220A CN201210471522A CN102961704A CN 102961704 A CN102961704 A CN 102961704A CN 2012104715220 A CN2012104715220 A CN 2012104715220A CN 201210471522 A CN201210471522 A CN 201210471522A CN 102961704 A CN102961704 A CN 102961704A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- rhizoma
- stir
- processed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating the liver caner and a method for preparing dispersible tablets thereof. The pharmaceutical composition is prepared from the following components in parts by weight: 39 parts of American ginseng, 25 parts of fried rhizoma atractylodis, 39 parts of fried fructus aurantii, 29 parts of rhizoma sparganic with vinegar, 29 parts of curcuma zedoary with vinegar, 39 parts of fried hawthorn, 73 parts of roasted turtle shell, 29 parts of stir-baked squama manitis, 34 parts of prepared rhizoma cyperi, 34 parts of prepared rhizoma corydalis, 44 parts of grifola, 25 parts of ligusticum wallichii, 2 parts of red flower, 29 parts of angelica sinensis, 29 parts of radix paeoniae alba, 39 parts of morinda meat, 39 parts of parasitic loranthus, 39 parts of semen cuscutae, 34 parts of schisandra chinensis, 39 parts of glossy privet fruit, 29 parts of pulp of dogwood fruit, 34 parts of fructus lycii, 2 parts of fennel, 29 parts of fructus amomi, 2 parts of dried ginger, 2 parts of cinnamon, 34 parts of sculellaria barbata, 34 parts of oldenlandia diffusa, 2 parts of amber powder, 2 parts of sanchi powder and 29 parts of centipede. The medicament provided by the invention is expected to achieve the effect of treating the liver cancer, and is prepared through scientific and rational production process with pure Chinese herbal medicines as major raw materials; and the product is clear in function, controllable in quality and safe for taking.
Description
Technical field
The invention belongs to field of pharmaceutical technology, relate to a kind of medicine dispersible tablet, particularly a kind of pharmaceutical composition and dispersible tablet preparation method thereof that is used for the treatment of hepatocarcinoma.
Background technology
The expection of developing drugs combination product reaches the treatment function of Hepatoma therapy.This product according to theory of Chinese medical science, adopts scientific and reasonable production technology to process take pure Chinese medicine as primary raw material, and this product function is clear and definite, and is quality controllable, takes safety.
Hepatocarcinoma refers to betide the malignant tumor of liver, comprises two kinds of primary hepatocarcinoma and secondary liver cancers, and mostly the hepatocarcinoma of the daily theory of people is primary hepatocarcinoma if referring to.Primary hepatocarcinoma is one of modal malignant tumor clinically, and according to recent statistics, the annual new liver cancer patient in the whole world is about 600,000, occupies the 5th of malignant tumor.Primary hepatocarcinoma can be divided into Hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed carcinoma of liver by cell typing.Form by tumor can be divided into nodular type, massive type and diffuse type.The traditional Chinese medical science thinks that to the pathogenesis understanding of hepatocarcinoma inside and outside combined pathogens produces multiple pathological factor, such as the stagnation of QI, and blood stasis, expectorant is solidifying, turbid damp, damp and hot, the fire stagnation pyretic toxicity is crisscross to be mingled with, and then gives birth in the cancer poison.The cancer poison is the pathology key that hepatocarcinoma is caused a disease.
The present invention is a kind of pure Chinese medicinal preparation, with Carapax Trionycis (processed), and Polyporus, Radix Morindae Officinalis, Semen Cuscutae is monarch drug, assistant Rhizoma Atractylodis (parched), Fructus Aurantii (parched), stir-baked RHIZOMA SPARGANII with vinegar, stir-baked RHIIZOMA CURCUMAE with vinegar, Rhizoma Corydalis processed, vital energy regualting and blood circulation-promoting, the collateral dredging removing food stagnancy, the loose joint of softening the hard mass, function of spleen and stomach regulating comprehensively reaches the function of Hepatoma therapy, take safety, can not produce dependency.
Summary of the invention
Purpose of the present invention aims to provide a kind of pharmaceutical composition and dispersible tablet preparation method thereof that is used for the treatment of hepatocarcinoma, and this pharmaceutical composition is a kind of take pure Chinese medicine as main medicine dispersible tablet, vital energy regualting and blood circulation-promoting, the collateral dredging removing food stagnancy, the loose joint of softening the hard mass, function of spleen and stomach regulating comprehensively reaches the function of Hepatoma therapy.
Technical scheme of the present invention is: design a kind of pharmaceutical composition and dispersible tablet preparation method thereof that is used for the treatment of hepatocarcinoma, it is characterized in that composition and weight proportion thereof that it contains are: 39 parts of Radix Panacis Quinquefoliis, 25 parts of Rhizoma Atractylodis (parched), 39 parts of Fructus Aurantii (parched), 29 parts of stir-baked RHIZOMA SPARGANII with vinegar, 29 parts of stir-baked RHIIZOMA CURCUMAE with vinegar, 39 parts of Fructus Crataegi (parched), 73 parts of Carapax Trionycis (processed), 29 parts of stir-baked SQUAMA MANITISs, 34 parts of Rhizoma Cyperi (processed), 34 parts of Rhizoma Corydalis processed, 44 parts of Polyporus, 25 parts of Rhizoma Chuanxiongs, 2 parts on Flos Carthami, 29 parts of Radix Angelicae Sinensis, 29 parts of the Radix Paeoniae Albas, 39 parts of Radix Morindae Officinaliss, 39 parts of Herba Taxillis, 39 parts of Semen Cuscutae, 34 parts of Fructus Schisandrae Chinensis, 39 parts of Fructus Ligustri Lucidi, 29 parts of Fructus Corni, 34 parts of Fructus Lycii, 2 parts of Fructus Foeniculi, 29 parts of Fructus Amomis, 2 parts of Rhizoma Zingiberiss, 2 parts of Cortex Cinnamomis, 34 parts of Herba Scutellariae Barbataes, 34 parts of Herba Hedyotidis Diffusaes, 2 parts of Succinum powder, 2 parts of Radix Notoginseng powder, 29 parts of Scolopendras.
A kind of preparation method that is used for the treatment of the pharmaceutical composition of hepatocarcinoma is characterized in that it may further comprise the steps;
1) by following weight proportion weighting raw materials: 39 parts of Radix Panacis Quinquefoliis, 25 parts of Rhizoma Atractylodis (parched), 39 parts of Fructus Aurantii (parched), 29 parts of stir-baked RHIZOMA SPARGANII with vinegar, 29 parts of stir-baked RHIIZOMA CURCUMAE with vinegar, 39 parts of Fructus Crataegi (parched), 73 parts of Carapax Trionycis (processed), 29 parts of stir-baked SQUAMA MANITISs, 34 parts of Rhizoma Cyperi (processed), 34 parts of Rhizoma Corydalis processed, 44 parts of Polyporus, 25 parts of Rhizoma Chuanxiongs, 2 parts on Flos Carthami, 29 parts of Radix Angelicae Sinensis, 29 parts of the Radix Paeoniae Albas, 39 parts of Radix Morindae Officinaliss, 39 parts of Herba Taxillis, 39 parts of Semen Cuscutae, 34 parts of Fructus Schisandrae Chinensis, 39 parts of Fructus Ligustri Lucidi, 29 parts of Fructus Corni, 34 parts of Fructus Lycii, 2 parts of Fructus Foeniculi, 29 parts of Fructus Amomis, 2 parts of Rhizoma Zingiberiss, 2 parts of Cortex Cinnamomis, 34 parts of Herba Scutellariae Barbataes, 34 parts of Herba Hedyotidis Diffusaes, 2 parts of Succinum powder, 2 parts of Radix Notoginseng powder, 29 parts of Scolopendras;
2) decoct with water secondary in the above raw material, 2.5 hours for the first time, 1.5 hours for the second time, filter, close and hand over and filtrate, the clear paste of 1.32～1.35 () when filtrate decompression is concentrated into relative density and is 50 ℃;
3) above-mentioned clear paste, 50 ℃ of drying under reduced pressure were pulverized 60 mesh sieves, became dried cream powder for subsequent use;
4) with the aspartame of dried cream powder in the step 3) and 50 parts, cross 60 mesh sieves;
5) with the raw material mix homogeneously that sieves of step 4), with ethanol soft material processed;
6) 14 mesh sieves are granulated, 50-60 ℃ of forced air drying;
7) 14 mesh sieve granulate add 12 parts magnesium stearate, mix homogeneously.
8) tabletting gets final product.
Advantage of the present invention, the Carapax Trionycis (processed) salty in the mouth in this component, property are put down.Have nourishing YIN for suppressing the hyperactive YANG, hard masses softening and resolving is brought down a fever except steaming.Be used for fever due to yin deficiency, consumptive fever hectic fever due to YIN-deficiency, stirring-up of pathogenic wind in the interior resulting from deficiency, amenorrhea ， WEIJIA, chronic malaria malaria with splenomegaly.Herba Taxilli is bitter, and is sweet, and property is flat.Has invigorating the liver and kidney; Bone and muscle strengthening; Wind-damp dispelling; Antiabortive.Main soreness of waist and knee joint; A little less than the muscles and bones flaccidity; Limbs are hemiplegia; Rheumatic arthralgia; Head is wrong dizzy; Frequent fetal movement, metrostaxis.Be used for rheumatic arthralgia, soreness of the waist and knees, muscles and bones is unable, and the metrorrhagia warp is many, blood leaking in gestation, frequent fetal movement; Hypertension.Semen Cuscutae acrid in the mouth, sweet, slightly warm in nature; Return the liver,kidney,spleen warp; Gas and property are slow, can float to sink to have the kidney invigorating and essence nourishing nourishing the liver to improve visual acuity, the solid tire of spleen invigorating.Cure mainly lumbago tinnitus, impotence and seminal emission is quenched one's thirst, and is sterile, enuresis incontinence, and the stranguria with turbid discharge leukorrhagia, the head is dim, and lack of appetite is had loose bowels, frequent fetal movement.Rhizoma Atractylodis (parched) is hot, bitter, temperature.Return spleen, stomach, Liver Channel.Have drying damp and strengthening spleenly, expelling wind and cold makes eye bright.Be used for distension and fullness in the abdomen, have loose bowels edema, rheumatic arthralgia, anemofrigid cold, nyctalopia.Fructus Aurantii (parched) is bitter, hot, sour, temperature.Return spleen, stomach warp.Has regulating the flow of QI to ease the stomach, the stagnant relieving distension of row.Be used for the breast side of body stagnation of QI, distension pain, accumulation of food in the stomach and intes tine due to indigestion stops in the phlegm retention; Gastroptosis, proctoptosis, sub-official's prolapsus.Fructus Crataegi (parched) spleen benefiting and stimulating the appetite, relieving dyspepsia, phlegm reduction of blood circulation promoting.This product is with Carapax Trionycis (processed), Polyporus, and Radix Morindae Officinalis, Semen Cuscutae are monarch drug, assistant Rhizoma Atractylodis (parched), Fructus Aurantii (parched), stir-baked RHIZOMA SPARGANII with vinegar, stir-baked RHIIZOMA CURCUMAE with vinegar, Rhizoma Corydalis processed, vital energy regualting and blood circulation-promoting, collateral dredging removing food stagnancy, the loose joint of softening the hard mass, function of spleen and stomach regulating, comprehensively reach the function of Hepatoma therapy, safety, reliable, no dependence.This prescription not only can Hepatoma therapy, and other diseases is also had auxiliary therapeutic action.
The specific embodiment
The invention will be further described below in conjunction with specific embodiment, but not as limitation of the present invention.The part that is not described in detail in the present embodiment is to adopt prior art, and industry standard or known approaches.
Embodiment 1
Adopt following steps to make by described a kind of pharmaceutical composition and the dispersible tablet preparation method thereof that is used for the treatment of hepatocarcinoma of claim 1:
1) by following weight proportion weighting raw materials: 39 parts of Radix Panacis Quinquefoliis, 25 parts of Rhizoma Atractylodis (parched), 39 parts of Fructus Aurantii (parched), 29 parts of stir-baked RHIZOMA SPARGANII with vinegar, 29 parts of stir-baked RHIIZOMA CURCUMAE with vinegar, 39 parts of Fructus Crataegi (parched), 73 parts of Carapax Trionycis (processed), 29 parts of stir-baked SQUAMA MANITISs, 34 parts of Rhizoma Cyperi (processed), 34 parts of Rhizoma Corydalis processed, 44 parts of Polyporus, 25 parts of Rhizoma Chuanxiongs, 2 parts on Flos Carthami, 29 parts of Radix Angelicae Sinensis, 29 parts of the Radix Paeoniae Albas, 39 parts of Radix Morindae Officinaliss, 39 parts of Herba Taxillis, 39 parts of Semen Cuscutae, 34 parts of Fructus Schisandrae Chinensis, 39 parts of Fructus Ligustri Lucidi, 29 parts of Fructus Corni, 34 parts of Fructus Lycii, 2 parts of Fructus Foeniculi, 29 parts of Fructus Amomis, 2 parts of Rhizoma Zingiberiss, 2 parts of Cortex Cinnamomis, 34 parts of Herba Scutellariae Barbataes, 34 parts of Herba Hedyotidis Diffusaes, 2 parts of Succinum powder, 2 parts of Radix Notoginseng powder, 29 parts of Scolopendras;
2) decoct with water secondary in the above raw material, 2.5 hours for the first time, 1.5 hours for the second time, filter, close and hand over and filtrate, the clear paste of 1.32～1.35 () when filtrate decompression is concentrated into relative density and is 50 ℃;
3) above-mentioned clear paste, 50 ℃ of drying under reduced pressure were pulverized 60 mesh sieves, became dried cream powder for subsequent use;
4) with the aspartame of dried cream powder in the step 3) and 50 parts, cross 60 mesh sieves;
5) with the raw material mix homogeneously that sieves of step 4), with ethanol soft material processed;
6) 14 mesh sieves are granulated, 50-60 ℃ of forced air drying;
7) 14 mesh sieve granulate add 12 parts magnesium stearate, mix homogeneously.
8) tabletting gets final product.
This dosage form is dispersible tablet.
The embodiment of the invention 1 is this to be used for the treatment of the clinical observation of dispersible tablet Hepatoma therapy of the pure Chinese medicine of hepatocarcinoma
1 data and method
1.1 physical data
Liver cancer patient 80 examples that selection is received treatment voluntarily are divided into each 20 example for the treatment of group and matched group at random, 12 for the treatment of group men, 8 of woman; Age is between 38-60; 11 of matched group men, 9 of woman; Each organizes patient age symptom formation without significant difference, and disease time is the longest 5 years, the shortest January.Has comparability (P〉5).
1.2 Therapeutic Method
The treatment group Primary Care is consistent, and matched group is not taken medicine.Treatment group 1 is used the embodiment of the invention, and three of every days twice, one time, 10 ~ 15 is a course for the treatment of.The gan fu le capsule for the treatment of group 2 usefulness Hunan Kang Pu pharmacy, each 6,3 times on the one.The FUFANG BANMAO JIAONANG for the treatment of group 3 usefulness Guizhou Yibai Pharmaceutical Co., Ltd, one time 3,2 times on the one.
2 results
2.1 curative effect determinate standard
Diagnostic criteria
(1) the pathological diagnosis 1. liver histological inspections person that turns out to be the primary hepatocarcinoma.2. the histological examination of extrahepatic tissue turns out to be hepatocarcinoma.(2) clinical diagnosis 1. as without other hepatocarcinoma evidences, the AFP convection current method positive or radioimmunology 〉=400ng/ml continue more than 4 weeks, and can get rid of gestation, activeness hepatopathy, gonad embryo source property tumor and secondary liver cancer person.2. imaging examination has Solid lesion pathological changes in the clear and definite liver, can get rid of hepatic haemangioma and secondary liver cancer, and have the one of following condition: (1) AFP 〉=200ng/ml.(2) typical primary hepatocarcinoma Radiologic imaging.(3) AKP or γ-GT obviously increase without jaundice.(4) clear and definite metastasis (metastases) is arranged or bloody ascites is arranged at a distance, or in ascites, find cancerous cell.(5) liver cirrhosis of the clear and definite hepatitis B sign positive.
Criterion
The objective curative effect of tumor body: according to WHO criterion of therapeutical effect: CR (alleviating fully), PR (partial rcsponse), SD (stablizing), PD(progress).CR: tumor disappears and continues more than 1 month.CR; Tumor disappears and continues more than 1 month.PR: it is above and lasting more than 1 month that the orthogonal diameter product of two maximums of tumor dwindles 50 %.SD: the orthogonal diameter product of two maximums of tumor dwindles less than 50 %, increases to be no more than 25% and lasting more than 1 month.PD; The orthogonal diameter product of two maximums of tumor increases above 25%.
2.2 therapeutic outcome
| ? | CR | PR | SD | PD | Effective percentage |
| Matched group | 0 | 0 | 0 | 20 | 0 |
| Treatment group 1 | 9 | 6 | 4 | 1 | 95% |
| Treatment group 2 | 7 | 7 | 4 | 2 | 90% |
| Treatment group 3 | 6 | 8 | 3 | 3 | 85% |
3 discuss
The traditional Chinese medical science thinks that to the pathogenesis understanding of hepatocarcinoma inside and outside combined pathogens produces multiple pathological factor, such as the stagnation of QI, and blood stasis, expectorant is solidifying, turbid damp, damp and hot, the fire stagnation pyretic toxicity is crisscross to be mingled with, and then gives birth in the cancer poison.The cancer poison is the pathology key that hepatocarcinoma is caused a disease.Adopting the present invention to make up can vital energy regualting and blood circulation-promoting, the collateral dredging removing food stagnancy, and the loose joint of softening the hard mass, function of spleen and stomach regulating comprehensively reaches the function of Hepatoma therapy.And then illustrate that embodiment 1 affiliated prescription is reliably effective in this invention.
Claims (2)
1. pharmaceutical composition that is used for the treatment of hepatocarcinoma is characterized in that composition and weight proportion thereof that it contains are:
39 parts of Radix Panacis Quinquefoliis, 25 parts of Rhizoma Atractylodis (parched), 39 parts of Fructus Aurantii (parched), 29 parts of stir-baked RHIZOMA SPARGANII with vinegar, 29 parts of stir-baked RHIIZOMA CURCUMAE with vinegar, 39 parts of Fructus Crataegi (parched), 73 parts of Carapax Trionycis (processed), 29 parts of stir-baked SQUAMA MANITISs, 34 parts of Rhizoma Cyperi (processed), 34 parts of Rhizoma Corydalis processed, 44 parts of Polyporus, 25 parts of Rhizoma Chuanxiongs, 2 parts on Flos Carthami, 29 parts of Radix Angelicae Sinensis, 29 parts of the Radix Paeoniae Albas, 39 parts of Radix Morindae Officinaliss, 39 parts of Herba Taxillis, 39 parts of Semen Cuscutae, 34 parts of Fructus Schisandrae Chinensis, 39 parts of Fructus Ligustri Lucidi, 29 parts of Fructus Corni, 34 parts of Fructus Lycii, 2 parts of Fructus Foeniculi, 29 parts of Fructus Amomis, 2 parts of Rhizoma Zingiberiss, 2 parts of Cortex Cinnamomis, 34 parts of Herba Scutellariae Barbataes, 34 parts of Herba Hedyotidis Diffusaes, 2 parts of Succinum powder, 2 parts of Radix Notoginseng powder, 29 parts of Scolopendras.
2. by the described a kind of preparation method that is used for the treatment of the pharmaceutical composition of hepatocarcinoma of claim 1, it may further comprise the steps:
1) by following weight proportion weighting raw materials: 39 parts of Radix Panacis Quinquefoliis, 25 parts of Rhizoma Atractylodis (parched), 39 parts of Fructus Aurantii (parched), 29 parts of stir-baked RHIZOMA SPARGANII with vinegar, 29 parts of stir-baked RHIIZOMA CURCUMAE with vinegar, 39 parts of Fructus Crataegi (parched), 73 parts of Carapax Trionycis (processed), 29 parts of stir-baked SQUAMA MANITISs, 34 parts of Rhizoma Cyperi (processed), 34 parts of Rhizoma Corydalis processed, 44 parts of Polyporus, 25 parts of Rhizoma Chuanxiongs, 2 parts on Flos Carthami, 29 parts of Radix Angelicae Sinensis, 29 parts of the Radix Paeoniae Albas, 39 parts of Radix Morindae Officinaliss, 39 parts of Herba Taxillis, 39 parts of Semen Cuscutae, 34 parts of Fructus Schisandrae Chinensis, 39 parts of Fructus Ligustri Lucidi, 29 parts of Fructus Corni, 34 parts of Fructus Lycii, 2 parts of Fructus Foeniculi, 29 parts of Fructus Amomis, 2 parts of Rhizoma Zingiberiss, 2 parts of Cortex Cinnamomis, 34 parts of Herba Scutellariae Barbataes, 34 parts of Herba Hedyotidis Diffusaes, 2 parts of Succinum powder, 2 parts of Radix Notoginseng powder, 29 parts of Scolopendras;
2) decoct with water secondary in the above raw material, 2.5 hours for the first time, 1.5 hours for the second time, filter, close and hand over and filtrate, the clear paste of 1.32～1.35 () when filtrate decompression is concentrated into relative density and is 50 ℃;
3) above-mentioned clear paste, 50 ℃ of drying under reduced pressure were pulverized 60 mesh sieves, became dried cream powder for subsequent use;
4) with the aspartame of dried cream powder in the step 3) and 50 parts, cross 60 mesh sieves;
5) with the raw material mix homogeneously that sieves of step 4), with ethanol soft material processed;
6) 14 mesh sieves are granulated, 50-60 ℃ of forced air drying;
7) 14 mesh sieve granulate add 12 parts magnesium stearate, mix homogeneously;
8) tabletting gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104715220A CN102961704A (en) | 2012-11-20 | 2012-11-20 | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104715220A CN102961704A (en) | 2012-11-20 | 2012-11-20 | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102961704A true CN102961704A (en) | 2013-03-13 |
Family
ID=47792323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104715220A Withdrawn CN102961704A (en) | 2012-11-20 | 2012-11-20 | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961704A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367744A (en) * | 2014-09-28 | 2015-02-25 | 刘铁军 | Blood stasis dissolving and dispersing granule and its preparation technology |
| CN105233173A (en) * | 2015-11-11 | 2016-01-13 | 梁占强 | Composition for treating tumors of livers, gall and pancreas and preparation method thereof |
-
2012
- 2012-11-20 CN CN2012104715220A patent/CN102961704A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367744A (en) * | 2014-09-28 | 2015-02-25 | 刘铁军 | Blood stasis dissolving and dispersing granule and its preparation technology |
| CN105233173A (en) * | 2015-11-11 | 2016-01-13 | 梁占强 | Composition for treating tumors of livers, gall and pancreas and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102847064A (en) | Chinese herbal medicine used for inhibition of malignant tumor metastasis | |
| CN102048893B (en) | Traditional Chinese medicine composition for treating arthromyodynia | |
| CN103007226A (en) | Drug for treating hepatocirrhosis ascites, and preparation method thereof | |
| CN102526498A (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN103893738A (en) | Traditional Chinese medicine composition for inhibiting tumor growth and preparation method thereof | |
| CN103638451A (en) | Traditional Chinese medicine for treating chronic hepatitis and preparation method thereof | |
| CN105288537A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparing method thereof | |
| CN102698210A (en) | Traditional Chinese medicine capable of invigorating spleen and supplementing qi and treating gastroptosis | |
| CN102327572B (en) | Chinese medicament for invigorating primordial energy and treating gastroptosis and extraction method thereof | |
| CN104984296A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof | |
| CN102961704A (en) | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof | |
| CN103285343A (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN103690869B (en) | Chinese medicine for the treatment of irritable bowel syndrome and preparation method thereof | |
| CN105535839A (en) | Traditional Chinese medicine tablets for treating colon cancer and preparation method thereof | |
| CN104825817A (en) | Traditional Chinese medicine preparation with antitumor effect | |
| CN105250959A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method | |
| CN102961708A (en) | Pure traditional Chinese medicine compound preparation for treating nephritic syndrome and capsule preparation method thereof | |
| CN103656199B (en) | A kind of Chinese medicine for the treatment of deficiency of kidney yin syndrome cough | |
| CN103494939A (en) | Traditional Chinese medicine for treating senile habitual constipation | |
| CN104547875A (en) | Traditional Chinese medicine for treating arteries and veins stasis type chest stuffiness and pain | |
| CN103285130B (en) | Chinese medicine composition for liver cancer treatment and preparing method thereof | |
| CN101773643B (en) | Chinese medicine preparation for treating mammary gland proliferation diseases and preparation method thereof | |
| CN105597004A (en) | Traditional Chinese medicine combination for treating cancer | |
| CN105902885A (en) | Traditional Chinese medicine for treatment of lung cancer | |
| CN105688158B (en) | A kind of Chinese materia medica preparation and preparation method thereof for treating autoimmune liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20130313 |